title: Baseline C-reactive protein serum levels and in-stent restenosis pattern after m-TOR inhibitors drug-eluting stent implantation.
abstract: BACKGROUND
  A diffuse pattern of in-stent restenosis (ISR) has been shown to have a worse prognosis when compared to a focal pattern. It is still unknown whether baseline C-reactive protein (CRP) levels predict ISR pattern.
  
  
  METHODS
  Our database was searched retrospectively for patients presenting with ISR after m-TOR inhibitor drug-eluting stent (DES) implantation from January 2007 to December 2009. Angiographic restenosis patterns were evaluated according to the simplified Mehran classification and patients were allocated either to the diffuse or focal pattern group. Predictors of restenosis pattern were assessed among clinical, angiographic, procedural and laboratory data, including baseline high-sensitivity CRP, recorded at the time of the first percutaneous intervention.
  
  
  RESULTS
  72 patients (age, 65 ± 9 years; male sex, 64%) found to have ISR after DES implantation were enrolled. 34 patients presented with a focal pattern, whereas 38 patients presented with a diffuse pattern. At multivariate analysis, CRP levels were the only independent predictor of a diffuse ISR pattern [odds ratio, 2.5; 95% confidence interval, 1.4-4.3; p = 0.001)]. Rising CRP tertiles were associated with an increased rate of diffuse pattern (13% versus 26% versus 61%; p for trend = 0.0001).
  
  
  CONCLUSIONS
  Baseline CRP serum levels are associated with a diffuse ISR pattern after m-TOR inhibitor DES implantation. These findings suggest that baseline inflammatory reactivity may contribute to aggressive restenosis occurring despite drug elution.
authors.affiliation: Catholic University of the Sacred Heart, Cardiovascular Medicine, L.go F. Vito 1, Rome 00168, Italy. gniccoli73@hotmail.it
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Niccoli
authors.forename: Micaela
authors.initials: M
authors.lastname: Conte
authors.forename: Nicola
authors.initials: N
authors.lastname: Cosentino
authors.forename: Daniel
authors.initials: D
authors.lastname: Todaro
authors.forename: Salvatore
authors.initials: S
authors.lastname: Brugaletta
authors.forename: Rocco Antonio
authors.initials: RA
authors.lastname: Montone
authors.forename: Silvia
authors.initials: S
authors.lastname: Minelli
authors.forename: Francesco
authors.initials: F
authors.lastname: Fracassi
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Galiffa
authors.forename: Antonio Maria
authors.initials: AM
authors.lastname: Leone
authors.forename: Francesco
authors.initials: F
authors.lastname: Burzotta
authors.forename: Italo
authors.initials: I
authors.lastname: Porto
authors.forename: Carlo
authors.initials: C
authors.lastname: Trani
authors.forename: Filippo
authors.initials: F
authors.lastname: Crea
mesh_terms: D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis*; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000097:blood* / Q000145:classification / Q000000981:diagnostic imaging / Q000473:pathology*; D003925:Diabetic Angiopathies / Q000097:blood / Q000473:pathology / Q000628:therapy; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000097:blood / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D019919:Prosthesis Implantation; D012189:Retrospective Studies; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D002097:C-Reactive Protein; D058570:TOR Serine-Threonine Kinases